Prospective, biological, observational study involving the collection and use of samples from patients suffering from NSCLC lung cancer, aimed at comparing the molecular profile related to metabolism among subjects with response or resistance to checkpoint inhibitors immune system (ICI), in order to contribute to define response biomarkers and new molecular pathways as therapeutic targets combine with ICI to overcome resistance.
Age > 18 years
Histological diagnosis of advanced stage NSCLC
Histotype adenocarcinoma and squamous carcinoma
ECOG PS <2
Contraindications to immunotherapy
Unavailability of tumor tissue
Histotype with neuroendocrine or mixed component
Contraindication to immunotherapy
Patients suffering from NSCLC lung cancer
Family-based
Prospective
Not listed
Overall survival OS
The application of spatial transcriptomic approaches will enable the discovery of specific cellular niches that may be responsible for mechanisms of sensitivity or resistance to ICI. With the results you get, you will probably have a chance to locate it new and wonderful metabolic pathways capable of exerting their anti-tumor effect even in combination with ICIs.
Click on the lead sponsor to view all of their trials.
Regina Elena Cancer Institute
Lead sponsor
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Collaborator
